Open in Screener

TRML

Tourmaline Bio Inc

Sep 18 • 03:38PM ET

47.69

-0.01 -0.01 %

Healthcare • Biotechnology • USA • NASD

Peers: XOMA PSTX CYTK ALLO BPMC ONC NBIX SRPT MRNA ALT

| Held by: IWM VTI IWN VXF IBB FESM IWC AVSC VTWO ITOT

Index	RUT	P/E	-	EPS (ttm)	-3.44	Insider Own	35.42%	Shs Outstand	25.69M	Perf Week	0.20%
Market Cap	1.23B	Forward P/E	-	EPS next Y	-4.07	Insider Trans	0.00%	Shs Float	16.59M	Perf Month	113.21%
Enterprise Value	986.30M	PEG	-	EPS next Q	-0.97	Inst Own	74.40%	Short Float	16.00%	Perf Quarter	183.39%
Income	-88.47M	P/S	-	EPS this Y	-21.92%	Inst Trans	0.69%	Short Ratio	3.83	Perf Half Y	189.41%
Sales	0.00M	P/B	4.73	EPS next Y	-15.54%	ROA	-28.81%	Short Interest	2.65M	Perf YTD	135.18%
Book/sh	10.09	P/C	5.12	EPS next 5Y	-15.25%	ROE	-29.62%	52W High	47.75 -0.12%	Perf Year	137.05%
Cash/sh	9.31	P/FCF	-	EPS past 3/5Y	43.97% 8.04%	ROIC	-34.13%	52W Low	11.56 312.59%	Perf 3Y	32.12%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.16% 4.22%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	6.66%	Oper. Margin	-	ATR (14)	1.64	Perf 10Y	-
Dividend Ex-Date	Oct 20, 2023	Quick Ratio	24.68	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	94.34	Recom	2.80
Dividend Gr. 3/5Y	- -	Current Ratio	24.68	EPS Q/Q	-31.89%	SMA20	41.44%	Beta	2.18	Target Price	47.94
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	84.20%	Rel Volume	1.75	Prev Close	47.70
Employees	74	LT Debt/Eq	0.00	Earnings	Aug 13 BMO	SMA200	147.12%	Avg Volume	692.94K	Price	47.69
IPO	May 07, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.54% -	Trades		Volume	1,144,404	Change	-0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-23-25	Initiated	Chardan Capital Markets	Buy	$70
Mar-06-25	Initiated	Wedbush	Outperform	$42
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$50
Nov-11-24	Reiterated	H.C. Wainwright	Buy	$48 → $49
Dec-15-23	Initiated	Jefferies	Buy	$41
Dec-04-23	Resumed	H.C. Wainwright	Buy	$48
Nov-17-23	Initiated	Truist	Buy	$43
Oct-31-23	Initiated	Guggenheim	Buy	$50
Oct-25-23	Initiated	Piper Sandler	Overweight	$65
Oct-20-22	Initiated	H.C. Wainwright	Buy	$18
Jul-05-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$20 → $8

Show Previous Ratings

Sep-10-25 11:06AM	NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline (Zacks)
Sep-09-25 04:06PM	Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' (Investor's Business Daily) +57.85%
10:36AM	Novartis & Tourmaline, Anglo American & Teck, CoreWeave AI fund (Yahoo Finance Video)
09:07AM	Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion (Investor's Business Daily)
07:28AM	This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. (Barrons.com)
05:39AM	Loading…
05:39AM	Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range (MarketWatch)
02:02AM	Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal (The Wall Street Journal)
01:03AM	Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG (GlobeNewswire)
Aug-31-25 10:23AM	Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress (GlobeNewswire)
Aug-15-25 09:55AM	Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know (Zacks)
Aug-13-25 07:00AM	Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-28-25 02:15PM	H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results (Insider Monkey)
May-22-25 05:25PM	BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) (Insider Monkey)
May-20-25 07:30AM	Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease (GlobeNewswire)
May-19-25 04:05PM	Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 (GlobeNewswire)
07:30AM	Loading…
May-02-25 07:30AM	Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -8.68%
Apr-03-25 01:59PM	Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data (Seeking Alpha)
Mar-13-25 07:30AM	Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-07-25 09:41AM	Robinhood initiated, MongoDB downgraded: Wall Streets top analyst calls (TipRanks)
Mar-03-25 07:15AM	Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire) -5.81%
Jan-27-25 07:00AM	Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-10-25 07:30AM	Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker (GlobeNewswire)
Dec-10-24 08:30AM	Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day (GlobeNewswire)
Nov-14-24 07:30AM	Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 (GlobeNewswire)
Nov-12-24 11:00PM	Tourmaline Bio, Inc. Reports Third Quarter Financial Results (TipRanks) -7.63%
Nov-07-24 07:30AM	Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-31-24 07:30AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-15-24 07:30AM	Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 (GlobeNewswire)
Oct-11-24 07:30AM	Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress (GlobeNewswire) -8.48%
Oct-08-24 07:30AM	Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board (GlobeNewswire) +6.86%
07:45AM	Loading…
Sep-03-24 07:45AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:30AM	Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +6.13%
Aug-02-24 04:30PM	Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024 (GlobeNewswire) -8.09%
Jun-27-24 08:05AM	Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer (GlobeNewswire) -5.84%
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
May-23-24 07:10AM	Tourmaline Bio to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 07:00AM	Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial (GlobeNewswire)
May-13-24 01:54PM	TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-02-24 07:00AM	Avalo Therapeutics Appoints Biotech Leaders to Board of Directors (GlobeNewswire) -7.39%
Mar-19-24 02:52PM	TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023 (InvestorPlace)
07:00AM	Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-15-24 08:50AM	Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going (Zacks)
Feb-28-24 08:50AM	Here's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price Strength (Zacks)
Feb-27-24 07:30AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-08-24 08:50AM	What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing' (Zacks)
Feb-01-24 08:00AM	Tourmaline Bio to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 04:01PM	Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-25-24 07:00AM	Tourmaline Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +7.33%
Jan-24-24 04:05PM	Tourmaline Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire) -6.37%
Jan-08-24 07:00AM	Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD) (GlobeNewswire) +9.25%
Dec-15-23 04:00PM	Tourmaline Bio added to the NASDAQ Biotechnology Index (GlobeNewswire) -5.00%
Dec-14-23 07:30AM	Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board (GlobeNewswire)
Nov-01-23 08:00AM	Tourmaline Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-26-23 09:02PM	CEO Sandeep Kulkarni Buys 9650 Shares of Tourmaline Bio Inc (GuruFocus.com) +5.83% +7.03%
Oct-19-23 05:37PM	Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million (GlobeNewswire) -59.93%
Oct-17-23 05:47PM	Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio (GlobeNewswire) -6.00%
Oct-06-23 05:09PM	Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio (GlobeNewswire)
Oct-04-23 08:30AM	New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics (GlobeNewswire)
Jun-22-23 07:30AM	Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement (GlobeNewswire) +22.73%
May-26-23 07:00AM	Talaris Therapeutics Announces Leadership Transition (GlobeNewswire)
May-20-23 08:18AM	Talaris Therapeutics, Inc. (NASDAQ:TALS) most popular amongst private equity firms who own 34% of the shares, institutions hold 30% (Simply Wall St.)
Feb-16-23 03:10PM	Wellesley biotech cuts one-third of staff, explores sale (American City Business Journals) +24.05%
07:00AM	Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan (GlobeNewswire)
Dec-25-22 09:25AM	We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth Carefully (Simply Wall St.)
Nov-22-22 07:00AM	Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-10-22 07:00AM	Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update (GlobeNewswire) +6.99%
Nov-07-22 07:00AM	Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance (GlobeNewswire)
Oct-21-22 11:28AM	Talaris (TALS) Down on Patient Death From Renal Transplant Study (Zacks)
Oct-20-22 02:27PM	HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space (Benzinga) -43.39%
10:26AM	Talaris Therapeutics Reports Patient Death In Late-Stage Trial Of Experimental Drug For Graft vs Host Disease (Benzinga)
08:24AM	Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial (MarketWatch)
07:00AM	Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial (GlobeNewswire)
Oct-17-22 07:00AM	Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting (GlobeNewswire) +6.96%
Oct-04-22 07:00AM	Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-21-22 07:00AM	Talaris Therapeutics to Present at William Blairs Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event (GlobeNewswire)
Sep-06-22 07:00AM	Talaris Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +6.19%
Aug-15-22 07:00AM	Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update (GlobeNewswire)
Jul-18-22 09:47AM	We Think Talaris Therapeutics (NASDAQ:TALS) Can Afford To Drive Business Growth (Simply Wall St.)
Jun-30-22 07:00AM	Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update (GlobeNewswire) -36.75%
Jun-07-22 04:01PM	Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022 (GlobeNewswire) -9.14%
Jun-01-22 07:00AM	Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study (GlobeNewswire)
May-31-22 07:00AM	Talaris Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +16.35%
May-17-22 04:01PM	Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +35.93% -14.51%
07:00AM	Talaris Therapeutics Announces Changes to Board of Directors (GlobeNewswire)
May-12-22 04:01PM	Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update (GlobeNewswire) -5.25%
May-02-22 07:00AM	Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress (GlobeNewswire)
Apr-28-22 11:45AM	10 Best Stocks Under $20 According to Billionaire Andreas Halvorsens Viking Global (Insider Monkey)
Apr-06-22 04:01PM	Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001 (GlobeNewswire)
Mar-22-22 04:01PM	Talaris Therapeutics to Participate at Two Upcoming Investor Conferences (GlobeNewswire) +5.50%
Mar-17-22 04:01PM	Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results (GlobeNewswire)
Feb-11-22 07:00AM	Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -9.18%
Feb-08-22 01:32PM	We're Hopeful That Talaris Therapeutics (NASDAQ:TALS) Will Use Its Cash Wisely (Simply Wall St.)
Jan-31-22 09:38AM	Altium Wealth Management LLC Buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate ... (GuruFocus.com)
Jan-06-22 07:00AM	Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-22 07:00AM	Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire)
Dec-20-21 07:00AM	Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index (GlobeNewswire) +17.30%
Dec-14-21 07:00AM	Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant (GlobeNewswire)
Nov-30-21 07:00AM	Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma (GlobeNewswire)
Nov-12-21 07:00AM	Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KANTOFF AARON	Director	Sep 05 '25	Option Exercise	2.08	47,890	99,526	93,281	Sep 09 06:00 PM

CNTA Centessa Pharmaceuticals plc ADR daily Stock Chart

Peers: VRTX REGN MRNA BMRN IONS ALNY SRPT NBIX INCY ZLAB

| Held by: IBB GWX TMSL ONEQ FMED BBC IBBQ BIB

Index	-	P/E	-	EPS (ttm)	-1.78	Insider Own	36.42%	Shs Outstand	133.91M	Perf Week	0.86%
Market Cap	3.06B	Forward P/E	-	EPS next Y	-1.61	Insider Trans	-0.08%	Shs Float	85.14M	Perf Month	31.86%
Enterprise Value	2.93B	PEG	-	EPS next Q	-0.39	Inst Own	56.11%	Short Float	6.19%	Perf Quarter	80.32%
Income	-230.47M	P/S	203.31	EPS this Y	33.21%	Inst Trans	-1.83%	Short Ratio	4.35	Perf Half Y	36.34%
Sales	15.06M	P/B	8.88	EPS next Y	-16.82%	ROA	-51.74%	Short Interest	5.27M	Perf YTD	36.51%
Book/sh	2.58	P/C	12.21	EPS next 5Y	5.70%	ROE	-72.95%	52W High	23.24 -1.61%	Perf Year	38.91%
Cash/sh	1.87	P/FCF	-	EPS past 3/5Y	21.40% -210.04%	ROIC	-49.84%	52W Low	9.60 138.18%	Perf 3Y	436.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.94%	Volatility	5.06% 6.31%	Perf 5Y	-
Dividend TTM	-	EV/Sales	194.51	EPS Y/Y TTM	-14.45%	Oper. Margin	-1374.49%	ATR (14)	1.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.12	Sales Y/Y TTM	117.83%	Profit Margin	-1530.61%	RSI (14)	71.65	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.12	EPS Q/Q	4.87%	SMA20	21.25%	Beta	1.51	Target Price	33.00
Payout	-	Debt/Eq	0.34	Sales Q/Q	-	SMA50	31.88%	Rel Volume	0.76	Prev Close	21.85
Employees	77	LT Debt/Eq	0.34	Earnings	Aug 12 BMO	SMA200	47.77%	Avg Volume	1.21M	Price	22.86
IPO	May 28, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.84% -	Trades		Volume	868,447	Change	4.65%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Initiated	Wells Fargo	Overweight	$31
Aug-29-25	Resumed	Oppenheimer	Outperform	$40
Jul-21-25	Initiated	Truist	Buy	$30
May-28-25	Initiated	Needham	Buy	$35
May-08-25	Initiated	Chardan Capital Markets	Buy	$30
Mar-31-25	Initiated	Piper Sandler	Overweight	$38
Jan-07-25	Initiated	TD Cowen	Buy
Sep-20-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$11 → $26
Sep-19-24	Initiated	B. Riley Securities	Buy	$33
Jul-18-24	Initiated	Oppenheimer	Outperform	$14
Nov-15-23	Upgrade	Jefferies	Hold → Buy	$4 → $11
Oct-26-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$4 → $8
Jun-21-23	Initiated	Evercore ISI	Outperform
Jun-12-23	Initiated	Guggenheim	Buy	$9
Mar-17-23	Initiated	SVB Securities	Outperform	$6
Aug-12-22	Downgrade	Morgan Stanley	Overweight → Underweight	$10 → $5
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$19
Jun-03-22	Downgrade	Jefferies	Buy → Hold	$37 → $4
Feb-11-22	Initiated	Goldman	Neutral	$12

Show Previous Ratings

Sep-15-25 09:09AM	LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data (Insider Monkey)
Sep-03-25 07:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire) -7.87%
Aug-29-25 09:38AM	Marvell downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
Aug-12-25 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 (GlobeNewswire)
Jul-21-25 04:12PM	Why Alkermes Tumbled On Its Positive Narcolepsy Study (Investor's Business Daily)
01:35PM	Loading…
01:35PM	Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. (Investor's Business Daily)
Jul-15-25 08:58AM	Centessa Pharmaceuticals Advances Neurological Drug ORX142 to Clinical Trials (Insider Monkey)
Jul-04-25 03:00AM	Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist (GlobeNewswire)
Jun-24-25 12:46PM	Centessa Pharmaceuticals Receives FDA Clearance for New Drug ORX142, Initiates Phase 1 Study (Insider Monkey) +9.23%
Jun-17-25 09:05AM	Centessa announces clearance of IND for ORX142 (TipRanks)
Jun-16-25 12:00PM	Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:00AM	Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year (GlobeNewswire)
Jun-04-25 09:55AM	Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet (Zacks) -6.21%
May-19-25 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 (GlobeNewswire)
12:01PM	Loading…
May-09-25 12:01PM	Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz (TipRanks)
May-05-25 07:59AM	Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey)
Apr-03-25 04:08PM	Centessa Pharmaceuticals: Smooth Move To New Programs, But Questions Remain (Seeking Alpha) -10.57%
Mar-24-25 07:00AM	Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 (GlobeNewswire) +5.59%
Mar-06-25 04:14PM	Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Jan-28-25 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-13-25 09:51AM	Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20? (Insider Monkey)
Jan-09-25 05:14PM	Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25? (Insider Monkey)
Jan-08-25 07:05AM	Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer (GlobeNewswire) -7.04%
Dec-20-24 10:31AM	Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday? (Insider Monkey)
Nov-13-24 06:15AM	Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing (BioPharma Dive) +6.35%
Nov-12-24 07:00AM	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update (GlobeNewswire)
Nov-04-24 07:30AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-12-24 10:18AM	Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech (Insider Monkey)
Oct-09-24 08:04AM	Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments (Insider Monkey)
06:00AM	Loading…
Sep-26-24 06:00AM	Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) (GlobeNewswire)
Sep-12-24 10:34PM	Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares (GlobeNewswire) +9.82% +12.52%
Sep-11-24 04:04PM	Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares (GlobeNewswire) -5.69%
Sep-10-24 04:34PM	Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
12:19PM	Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers (Benzinga)
11:18AM	Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
08:15AM	Investors are waking up to Centessas sleepiness drug (BioPharma Dive)
07:00AM	Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers (GlobeNewswire)
Aug-27-24 08:00AM	Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) (GlobeNewswire)
Aug-24-24 01:18AM	Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ... (GuruFocus.com)
Aug-21-24 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-24 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade (Zacks)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-10-24 07:00AM	Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer (GlobeNewswire)
May-28-24 09:35AM	Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA) (Zacks)
May-21-24 08:45AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-13-24 09:54PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:10PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 (GlobeNewswire)
Apr-24-24 04:47AM	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS (MT Newswires)
Apr-23-24 09:36PM	Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares (GlobeNewswire) -6.00%
06:00PM	Centessa Pharmaceuticals Eyes $100 Million in ADS Offering (MT Newswires)
04:17PM	Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares (GlobeNewswire)
Apr-22-24 07:00AM	Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 (GlobeNewswire) -5.39%
Mar-28-24 11:53PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
06:11PM	Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results (GuruFocus.com)
04:28PM	Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 (GlobeNewswire)
Mar-27-24 01:26AM	Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares (GuruFocus.com)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace) +5.18%
Feb-22-24 08:00AM	Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 07:00AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire) +24.13%
Jan-22-24 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Dec-13-23 08:00AM	Centessa Pharmaceuticals to Present at the 42 Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-23 12:05PM	Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia (GlobeNewswire)
Dec-05-23 09:55AM	Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire) -7.69%
Nov-16-23 09:55AM	Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know (Zacks)
Nov-14-23 07:28PM	Centessa Pharmaceuticals PLC Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) +6.25% +8.75%
Nov-13-23 04:05PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 (GlobeNewswire)
Nov-02-23 09:09AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors (GlobeNewswire)
Oct-30-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.32%
Oct-25-23 08:00AM	Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders (GlobeNewswire) -6.02%
Oct-03-23 08:00AM	Centessa Pharmaceuticals Announces Additions to Senior Leadership Team (GlobeNewswire)
Sep-04-23 10:51AM	Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why (Zacks)
Aug-31-23 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire) +6.35%
Aug-23-23 05:08PM	Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress (GlobeNewswire)
Aug-14-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 (GlobeNewswire)
Jul-10-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors (GlobeNewswire) +5.04%
May-24-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-22-23 07:00AM	Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B (GlobeNewswire)
May-12-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 (GlobeNewswire)
Apr-27-23 12:07PM	Centessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22% (Simply Wall St.) -5.71%
Mar-30-23 07:00AM	Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 (GlobeNewswire)
Mar-27-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-23-23 04:30PM	Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director (PR Newswire) +5.04%
08:32AM	Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings? (Zacks)
Mar-01-23 08:00AM	Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines (GlobeNewswire)
Feb-06-23 08:00AM	Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire)
Feb-02-23 08:00AM	Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-26-23 09:08AM	Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors (GlobeNewswire)
Dec-10-22 03:30PM	Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia (GlobeNewswire)
Nov-30-22 08:00AM	Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson (GlobeNewswire)
Nov-18-22 10:29AM	While institutions own 29% of Centessa Pharmaceuticals plc (NASDAQ:CNTA), private equity firms are its largest shareholders with 42% ownership (Simply Wall St.)
Nov-10-22 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022 (GlobeNewswire)
Nov-03-22 09:04AM	Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting (GlobeNewswire)
Oct-31-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-20-22 08:33AM	Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022) (GlobeNewswire)
Sep-14-22 09:00AM	Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B (GlobeNewswire) +8.92%
Sep-12-22 07:00AM	Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index (GlobeNewswire)

Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Accardi Mario Alberto	President, Orexin Program	Sep 16 '25	Sale	21.40	8,172	174,846	197,394	Sep 16 06:16 PM
Accardi Mario Alberto	Officer	Sep 16 '25	Proposed Sale	22.06	8,172	180,274		Sep 16 04:09 PM
HUSSAIN IQBAL J	General Counsel	Sep 15 '25	Option Exercise	5.84	6,000	35,040	111,386	Sep 15 06:37 PM
HUSSAIN IQBAL J	General Counsel	Sep 15 '25	Sale	21.85	6,000	131,101	105,386	Sep 15 06:37 PM
HUSSAIN IQBAL J	Officer	Sep 15 '25	Proposed Sale	21.81	6,000	130,860		Sep 15 04:09 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 10 '25	Option Exercise	9.42	25,000	235,500	146,503	Sep 11 05:50 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 09 '25	Option Exercise	8.01	24,792	198,584	146,295	Sep 11 05:50 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 10 '25	Sale	22.00	25,000	550,000	121,503	Sep 11 05:50 PM
Bush Tia L	Chief Technology & Quality Ofc	Sep 09 '25	Sale	20.00	24,792	495,840	121,503	Sep 11 05:50 PM
HUSSAIN IQBAL J	General Counsel	Sep 09 '25	Option Exercise	5.84	20,000	116,800	125,386	Sep 11 05:47 PM
HUSSAIN IQBAL J	General Counsel	Sep 10 '25	Option Exercise	5.84	20,000	116,800	125,386	Sep 11 05:47 PM
HUSSAIN IQBAL J	General Counsel	Sep 10 '25	Sale	22.00	20,000	440,000	105,386	Sep 11 05:47 PM
HUSSAIN IQBAL J	General Counsel	Sep 09 '25	Sale	20.01	20,000	400,102	105,386	Sep 11 05:47 PM
Accardi Mario Alberto	President, Orexin Program	Sep 09 '25	Option Exercise	8.01	5,000	40,050	212,566	Sep 11 05:45 PM
Accardi Mario Alberto	President, Orexin Program	Sep 09 '25	Sale	20.00	7,000	140,000	205,566	Sep 11 05:45 PM
Bush Tia L	Officer	Sep 10 '25	Proposed Sale	22.00	25,000	550,000		Sep 10 04:17 PM
HUSSAIN IQBAL J	Officer	Sep 10 '25	Proposed Sale	22.00	20,000	440,000		Sep 10 04:09 PM
Bush Tia L	Officer	Sep 09 '25	Proposed Sale	20.00	24,792	495,840		Sep 09 04:04 PM
Accardi Mario Alberto	Officer	Sep 09 '25	Proposed Sale	20.00	7,000	140,000		Sep 09 04:04 PM
HUSSAIN IQBAL J	Officer	Sep 09 '25	Proposed Sale	20.01	20,000	400,102		Sep 09 04:03 PM
HUSSAIN IQBAL J	General Counsel	Aug 15 '25	Option Exercise	5.84	6,000	35,040	111,386	Aug 15 06:13 PM
HUSSAIN IQBAL J	General Counsel	Aug 15 '25	Sale	17.23	6,000	103,380	105,386	Aug 15 06:13 PM
HUSSAIN IQBAL J	Officer	Aug 15 '25	Proposed Sale	17.23	6,000	103,380		Aug 15 04:03 PM
Accardi Mario Alberto	President, Orexin Program	Jul 29 '25	Sale	15.23	8,322	126,751	208,163	Jul 30 05:00 PM
Accardi Mario Alberto	Officer	Jul 29 '25	Proposed Sale	15.37	8,322	127,909		Jul 29 04:53 PM
Weinhoff Gregory M	Chief Business Officer	Jul 25 '25	Option Exercise	3.85	10,000	38,500	132,279	Jul 25 06:24 PM
Weinhoff Gregory M	Chief Business Officer	Jul 25 '25	Sale	15.56	10,000	155,598	122,279	Jul 25 06:24 PM
Weinhoff Gregory M	Officer	Jul 25 '25	Proposed Sale	15.56	10,000	155,598		Jul 25 04:05 PM
SAHA SAURABH	Chief Executive Officer	Jul 21 '25	Option Exercise	3.85	55,000	211,750	276,017	Jul 21 07:39 PM
SAHA SAURABH	Chief Executive Officer	Jul 21 '25	Sale	15.92	55,000	875,600	221,017	Jul 21 07:39 PM
SAHA SAURABH	Officer	Jul 21 '25	Proposed Sale	15.99	55,000	879,450		Jul 21 04:01 PM
CHAO DAVID M	Officer	Jul 17 '25	Proposed Sale	16.00	5,000	80,000		Jul 17 05:17 PM
CHAO DAVID M	Officer	Jul 15 '25	Proposed Sale	14.92	10,000	149,182		Jul 17 05:15 PM
HUSSAIN IQBAL J	General Counsel	Jul 15 '25	Option Exercise	5.84	6,000	35,040	111,386	Jul 17 04:15 PM
HUSSAIN IQBAL J	General Counsel	Jul 15 '25	Sale	14.93	6,000	89,567	105,386	Jul 17 04:15 PM
HUSSAIN IQBAL J	Officer	Jul 15 '25	Proposed Sale	14.93	6,000	89,567		Jul 15 04:04 PM
Weinhoff Gregory M	Chief Business Officer	Jun 25 '25	Option Exercise	3.85	10,000	38,500	132,279	Jun 25 07:44 PM
Weinhoff Gregory M	Chief Business Officer	Jun 25 '25	Sale	13.86	10,000	138,642	122,279	Jun 25 07:44 PM
HUSSAIN IQBAL J	General Counsel	Jun 24 '25	Option Exercise	5.84	12,000	70,080	117,386	Jun 25 07:43 PM
HUSSAIN IQBAL J	General Counsel	Jun 24 '25	Sale	14.02	12,000	168,218	105,386	Jun 25 07:43 PM
Accardi Mario Alberto	President, Orexin Program	Jun 24 '25	Option Exercise	3.85	15,000	57,750	231,485	Jun 25 07:42 PM
Accardi Mario Alberto	President, Orexin Program	Jun 24 '25	Sale	14.00	15,000	210,000	216,485	Jun 25 07:42 PM
Weinhoff Gregory M	Officer	Jun 25 '25	Proposed Sale	14.00	10,000	140,000		Jun 25 04:06 PM
Accardi Mario Alberto	Officer	Jun 24 '25	Proposed Sale	14.00	15,000	210,000		Jun 25 01:54 PM
HUSSAIN IQBAL J	Officer	Jun 24 '25	Proposed Sale	14.02	12,000	168,218		Jun 24 04:09 PM
SAHA SAURABH	Chief Executive Officer	Jun 20 '25	Option Exercise	3.85	55,000	211,750	276,017	Jun 20 08:58 PM
SAHA SAURABH	Chief Executive Officer	Jun 20 '25	Sale	12.63	55,000	694,826	221,017	Jun 20 08:58 PM
CHAO DAVID M	Officer	Jun 20 '25	Proposed Sale	12.87	10,000	128,650		Jun 20 04:14 PM
SAHA SAURABH	Officer	Jun 20 '25	Proposed Sale	12.87	55,000	707,575		Jun 20 04:14 PM
Weinhoff Gregory M	Chief Business Officer	May 27 '25	Option Exercise	3.85	10,000	38,500	132,279	May 27 06:31 PM
Weinhoff Gregory M	Chief Business Officer	May 27 '25	Sale	12.82	10,000	128,225	122,279	May 27 06:31 PM
Weinhoff Gregory M	Officer	May 27 '25	Proposed Sale	12.82	10,000	128,225		May 27 04:02 PM
SAHA SAURABH	Chief Executive Officer	May 20 '25	Option Exercise	3.85	55,000	211,750	276,017	May 20 05:44 PM
SAHA SAURABH	Chief Executive Officer	May 20 '25	Sale	12.71	55,000	699,110	221,017	May 20 05:44 PM
SAHA SAURABH	Officer	May 20 '25	Proposed Sale	12.74	55,000	700,700		May 20 04:19 PM
GOYAL ARJUN	Director	May 16 '25	Buy	12.73	417,646	5,315,005	462,585	May 19 05:49 PM
GOYAL ARJUN	Director	May 15 '25	Buy	12.24	44,939	550,238	44,939	May 19 05:49 PM
HUSSAIN IQBAL J	General Counsel	May 01 '25	Option Exercise	5.84	311	1,816	105,697	May 02 04:17 PM
HUSSAIN IQBAL J	General Counsel	May 01 '25	Sale	14.00	311	4,354	105,386	May 02 04:17 PM
HUSSAIN IQBAL J	General Counsel	Apr 25 '25	Option Exercise	5.84	3,609	21,077	108,995	Apr 29 04:58 PM
HUSSAIN IQBAL J	General Counsel	Apr 28 '25	Option Exercise	5.84	2,080	12,147	107,466	Apr 29 04:58 PM
HUSSAIN IQBAL J	General Counsel	Apr 25 '25	Sale	14.00	3,609	50,526	105,386	Apr 29 04:58 PM
HUSSAIN IQBAL J	General Counsel	Apr 28 '25	Sale	14.01	2,080	29,132	105,386	Apr 29 04:58 PM
HUSSAIN IQBAL J	Officer	Apr 28 '25	Proposed Sale	14.00	2,391	33,474		Apr 28 04:09 PM
Weinhoff Gregory M	Chief Business Officer	Apr 25 '25	Sale	13.61	11,742	159,857	122,279	Apr 25 08:20 PM
HUSSAIN IQBAL J	Officer	Apr 25 '25	Proposed Sale	14.00	3,609	50,526		Apr 25 04:20 PM
Weinhoff Gregory M	Officer	Apr 25 '25	Proposed Sale	13.49	11,742	158,399		Apr 25 04:12 PM
SAHA SAURABH	Chief Executive Officer	Apr 22 '25	Sale	12.43	40,344	501,476	221,017	Apr 22 05:43 PM
SAHA SAURABH	Chief Executive Officer	Apr 21 '25	Sale	12.29	14,656	180,100	261,361	Apr 22 05:43 PM
SAHA SAURABH	Officer	Apr 22 '25	Proposed Sale	12.43	40,344	501,476		Apr 22 04:46 PM
SAHA SAURABH	Officer	Apr 21 '25	Proposed Sale	12.21	14,656	178,950		Apr 21 04:14 PM
Weinhoff Gregory M	Chief Business Officer	Mar 25 '25	Option Exercise	3.85	10,000	38,500	144,021	Mar 26 04:16 PM
Weinhoff Gregory M	Chief Business Officer	Mar 25 '25	Sale	16.34	10,000	163,386	134,021	Mar 26 04:16 PM
Weinhoff Gregory M	Officer	Mar 25 '25	Proposed Sale	16.53	10,000	165,300		Mar 25 04:09 PM
SAHA SAURABH	Chief Executive Officer	Mar 20 '25	Sale	16.69	55,000	918,060	276,017	Mar 21 04:53 PM
SAHA SAURABH	Officer	Mar 20 '25	Proposed Sale	16.35	55,000	899,250		Mar 20 04:08 PM
CHAO DAVID M	Chief Administrative Officer	Mar 17 '25	Option Exercise	3.85	3,500	13,475	232,007	Mar 19 04:47 PM
CHAO DAVID M	Chief Administrative Officer	Mar 17 '25	Sale	17.17	7,000	120,206	225,007	Mar 19 04:47 PM
HUSSAIN IQBAL J	General Counsel	Mar 17 '25	Option Exercise	5.84	6,000	35,040	111,386	Mar 19 04:47 PM
HUSSAIN IQBAL J	General Counsel	Mar 17 '25	Sale	16.45	6,000	98,697	105,386	Mar 19 04:47 PM
HUSSAIN IQBAL J	Officer	Mar 17 '25	Proposed Sale	17.07	6,000	102,420		Mar 17 04:45 PM
CHAO DAVID M	Officer	Mar 17 '25	Proposed Sale	17.07	7,000	119,490		Mar 17 04:25 PM
Weinhoff Gregory M	Chief Business Officer	Feb 25 '25	Sale	15.25	11,494	175,270	134,021	Feb 26 04:24 PM
Weinhoff Gregory M	Officer	Feb 25 '25	Proposed Sale	15.25	11,494	175,270		Feb 25 04:03 PM
SAHA SAURABH	Chief Executive Officer	Feb 20 '25	Sale	15.93	55,000	876,088	331,017	Feb 20 05:45 PM
SAHA SAURABH	Officer	Feb 20 '25	Proposed Sale	15.90	55,000	874,500		Feb 20 04:14 PM
HUSSAIN IQBAL J	General Counsel	Feb 18 '25	Option Exercise	5.84	6,000	35,040	111,386	Feb 19 05:59 PM
HUSSAIN IQBAL J	General Counsel	Feb 18 '25	Sale	16.18	6,000	97,065	105,386	Feb 19 05:59 PM
HUSSAIN IQBAL J	Officer	Feb 18 '25	Proposed Sale	17.07	6,000	102,420		Feb 18 04:05 PM
Anderson Karen M.	Chief People Officer	Feb 07 '25	Option Exercise	4.01	30,526	122,409	84,848	Feb 10 05:33 PM
Anderson Karen M.	Chief People Officer	Feb 10 '25	Option Exercise	4.01	429	1,720	54,751	Feb 10 05:33 PM
Anderson Karen M.	Chief People Officer	Feb 07 '25	Sale	19.03	30,526	580,797	54,322	Feb 10 05:33 PM
Anderson Karen M.	Chief People Officer	Feb 10 '25	Sale	18.99	429	8,147	54,322	Feb 10 05:33 PM
Anderson Karen M.	Officer	Feb 10 '25	Proposed Sale	18.99	429	8,147		Feb 10 04:14 PM
Anderson Karen M.	Officer	Feb 07 '25	Proposed Sale	19.03	30,526	580,797		Feb 07 04:13 PM
Anderson Karen M.	Chief People Officer	Feb 03 '25	Sale	16.86	6,471	109,124	54,322	Feb 04 04:56 PM
Bush Tia L	Chief Technology & Quality Ofc	Feb 03 '25	Sale	16.86	11,000	185,406	121,503	Feb 04 04:55 PM
Bush Tia L	Officer	Feb 03 '25	Proposed Sale	16.49	11,000	181,390		Feb 03 04:08 PM
Anderson Karen M.	Officer	Feb 03 '25	Proposed Sale	16.49	6,471	106,707		Feb 03 04:04 PM
Weinhoff Gregory M	Chief Business Officer	Jan 27 '25	Sale	16.47	11,742	193,429	159,782	Jan 28 04:32 PM

TRML

Tourmaline Bio Inc

CNTA

Centessa Pharmaceuticals plc ADR

Upgrade your FINVIZ experience